Oculis Q2 2026 Earnings: Finance Gains Offset a Wider Operating Loss

Oculis (Nasdaq: OCS) reported Q2 2026 grant-based operating income of CHF 0.3 million, up from CHF 0.261 million a year earlier, while basic and diluted loss per share narrowed to CHF 0.16 from CHF 0.49. The quarterly operating loss widened as general and administrative spending increased, but warrant-liability and foreign-exchange gains reduced the reported net loss to CHF 10.0 million. Operationally, Oculis placed Privosegtor at the center of its neuro-ophthalmology strategy while PREDICT-1 enrollment for Licaminlimab passed 45%.

Core financial results

Oculis did not report product revenue for the quarter; its operating income consisted of CHF 0.310 million in grant income. Total operating expenses rose to CHF 23.9 million from CHF 21.0 million, primarily because of headcount-related costs, including share-based compensation, incurred to support the company’s development strategy.

The increase was concentrated in G&A expenses, which rose about 40%, while R&D expenses increased by approximately 3%. Consequently, the operating loss widened even though the reported net loss declined substantially.

Business and pipeline progress

Privosegtor becomes the lead strategic asset

Oculis continued its pivot toward neuro-ophthalmology, positioning Privosegtor as its lead late-stage candidate. Site activation for the PIONEER-1 registrational trial in optic neuritis is progressing across the U.S., Europe, Australia and Canada.

Under the Special Protocol Assessment agreement with the FDA, PIONEER-1’s primary endpoint is the proportion of patients achieving at least a 15-letter improvement in low-contrast visual acuity at Month 3. Patients will remain in the study through Month 12 for long-term safety and tolerability assessments.

The company is also preparing to expand Privosegtor into acute multiple sclerosis relapses. Following positive pre-IND feedback, the FDA indicated that Oculis would not need additional preclinical studies before submitting an IND that cross-references the existing optic neuritis filing. Oculis expects to submit that IND in the fourth quarter of 2026 and plans to provide further development updates at an R&D Day during the quarter.

Licaminlimab enrollment passes 45%

All planned sites are active in the PREDICT-1 registrational trial of Licaminlimab for dry eye disease, and more than 45% of patients have been randomized. The study plans to enroll approximately 160 patients, around two-thirds of whom are expected to have the specified TNFR1 genotype.

The primary endpoint measures the change in global ocular discomfort severity through Day 29 among patients with that genotype. Oculis expects topline results around the end of 2026. The genotype-based design is intended to identify patients more likely to respond, although the company noted that dry-eye symptom measurements are inherently subjective.

OCS-01 will not proceed to a DME filing

Following the DIAMOND topline results announced in May, Oculis said it does not currently plan to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema. That decision further concentrates the company’s development strategy around Privosegtor and Licaminlimab.

Finance gains narrowed the net loss despite a wider operating loss

The decline in Oculis’ quarterly net loss did not reflect improved operating profitability. Its operating loss increased by CHF 2.8 million year over year, but the finance result swung to a CHF 13.6 million gain from a CHF 4.6 million loss.

The largest contributor was a CHF 12.1 million fair-value gain on warrant liabilities, compared with a CHF 0.234 million loss in Q2 2025. Oculis also recorded a CHF 1.2 million foreign-exchange gain, versus a CHF 4.7 million loss a year earlier. These finance-result items explain why the net loss narrowed while the underlying operating loss widened.

The same distinction applies to the first six months of 2026. The first-half net loss narrowed to CHF 38.8 million from CHF 58.6 million, primarily because of warrant-liability fair-value movements and more favorable foreign-exchange effects rather than an improvement in operating results.

Liquidity and balance sheet

Oculis held CHF 228.3 million, or $282.3 million, in cash, cash equivalents and short-term investments as of June 30, 2026. That compared with CHF 213.0 million, or $268.7 million, at the end of 2025.

The balance included CHF 61.6 million in cash and cash equivalents and CHF 166.7 million in short-term financial assets. Management attributed the increase since year-end to proceeds from ordinary-share sales under the existing at-the-market offering program, partially offset by operating expenses. The company said its liquidity provides a cash runway into the second half of 2029.

Risks investors need to watch

• Privosegtor trial execution: PIONEER-1 depends on coordinated patient identification across emergency physicians, ophthalmologists and neurologists. Oculis also highlighted the seasonal pattern of optic neuritis enrollment, making site activation and recruitment timing important.
• Licaminlimab clinical uncertainty: PREDICT-1 relies on a genotype-selected population and a patient-reported ocular discomfort endpoint. The topline results must support the proposed precision-medicine approach.
• Greater pipeline concentration: The decision not to pursue an OCS-01 filing in diabetic macular edema leaves Privosegtor and Licaminlimab as the company’s two core clinical assets.
• Operating costs and equity financing: G&A expenses increased sharply, while the improvement in cash since year-end was supported by at-the-market share sales. Additional use of that program would increase the number of shares outstanding.
• Volatile reported losses: Warrant-liability remeasurement and currency movements had a large effect on Q2 net income, meaning reported net losses may not move in line with clinical-development spending.

Summary

Oculis’ Q2 2026 results presented two different financial trends: operating losses widened because of higher administrative spending, while finance gains sharply reduced the reported net loss. The company’s strategic focus has narrowed around Privosegtor and Licaminlimab, supported by $282.3 million in liquidity and a stated runway into the second half of 2029. The main upcoming points are PIONEER-1 execution, the planned acute-MS IND submission and year-end PREDICT-1 results.